Key Takeaways Amgen's growth is driven by newer drugs, biosimilars, and its Horizon deal despite looming patent losses. Novo Nordisk leads in GLP-1s, but faces competition, weak CagriSema data and a CEO transition. Amgen offers a stronger valuation and dividend yield, while Novo shows faster projected 2025 EPS growth.Amgen (AMGN) and Novo Nordisk (NVO) are among the largest companies in the pharmaceutical space.Amgen boasts one of the largest portfolios in the sector, with a strong presence in oncology, c ...